ArticleMicrobiology and immunology2026
Development of a Porcine Cell Line Stably Expressing Ephrin-B2 for Nipah Virus Research and Diagnostic Testing.
Article in Microbiology and immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of a Porcine Cell Line Stably Expressing Ephrin-B2 for Nipah Virus Research and Diagnostic Testing.Microbiology and immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nipah virus (NiV) is a highly pathogenic zoonotic virus transmitted from bats to humans through pigs as a crucial intermediate host. NiV outbreaks pose significant public health and economic threats, especially for pig farmers. Although the World Organization for Animal Health recommends African green monkey-derived Vero cells for NiV isolation, pig-derived cell lines could represent an optimal platform for propagating pig-origin NiV, as signs and symptoms of NiV infection differ among different hosts. In this study, we generated and evaluated pig-derived PK-15 cells stably expressing pig-derived ephrin-B2 (PK-15/Ephrin-B2 cells), the primary receptor for NiV. NiV pseudovirus infectivity was increased by > 1000-fold in PK-15/Ephrin-B2 cells compared with that in wild-type PK-15 cells, whereas virus susceptibility was higher in PK-15/Ephrin-B2 cells than in Vero cells (> 30-fold). Furthermore, Stat2-knockout PK-15/Ephrin-B2 cells exhibited stable viral infectivity in the presence of type I interferon, making it particularly suitable for clinical sample testing. Moreover, PK-15/Ephrin-B2 cells proved useful for neutralization tests using anti-NiV hyperimmune ascitic fluid. Therefore, PK-15 cells expressing pig ephrin-B2 could represent an efficient tool for virus isolation, vaccine development, and virological studies of NiV and related henipaviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.